From the MESOBLAST website... just to remind some of you this highly advanced stem cell company is well and truly in its final days as a minor player in the PHARMACEUTICAL world.
Highly probable (80% + ) FDA approval within the MONTH for a number of successful treatments and CURES?! YES?
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
The Company’s portfolio of Phase 3 product candidates are:
- RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) in children
- Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
- REVASCOR®for advanced chronic heart failure
- MPC-06-ID for chronic low back pain due to degenerative disc disease
Mesoblast’s Biologics License Application (BLA) for RYONCIL for the treatment of children with steroid-refractory acute GVHD has been accepted for priority review by the United States Food and Drug Administration (FDA). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020, and if approved, Mesoblast will make RYONCIL immediately available in the United States.
The Company also has a promising emerging pipeline and next generation technologies.
Innovative technology platform
Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.
Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes.
Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.
...............................................................................................
The following is a WEB page extract from a book
by MD Dr Allan C Somersall Phd(Author)
"Everybody has stem cells; everybody uses stem cells; everybody uses stem cells every day; stem cells work... and they work every time! This is a good story to tell in our generation. It's a story in two parts. First, there is the Natural Renewal System of the body which involves the release of those stem cells from the bone marrow. They then traffic to tissues in need where they migrate out, then proliferate and differentiate to become cells of each particular tissue, thereby providing an effective means for renewal and repair. "That's what nature does already - it is now proven basic Stem Cell physiology." Second, dietary intervention through Stem Cell Nutrition is now available to enhance this intrinsic process in a mild but significant way, thereby making the promotion of optimal health and wellness available to all - today, not tomorrow or whenever there is visible light on the research horizon, through Stem Cell Medicine. That's what you can do NOW to support your stem cell physiology! "I now realize that my own stem cells could hold the key to my future wellness and the prospect of a longer and healthier life. After reading this book, you will probably do what I did - practice Stem Cell Nutrition to keep your body healthy also."-Ambassador Raymond L. Flynn, Former Mayor of Boston and US Ambassador to the Vatican. Bestselling Author and TV Personality."
(20min delay)